查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1616879

藥品合約製造市場：按製造產品類型、按原料藥類型、按原料藥藥理活性、按FDF 類型、按劑型、按包裝類型、按業務規模、按最終用戶、按地區：2035 年之前和世界的行業趨勢預測

Pharmaceutical Contract Manufacturing Market by Type of Product Manufactured, Type of API, API Potency, Type of FDF, Dosage Form, Type of Packaging Offered, Scale of Operation, End Users and Regions: Industry Trends and Global Forecasts, Till 2035
出版日期: | 出版商: Roots Analysis | 英文 545 Pages | 商品交期: 最快1-2個工作天內

價格

全球藥品合約製造市場規模預計將從目前的 990 億美元成長到 2035 年的 1,560 億美元，到 2035 年的預測期間複合年增長率為 4.3%。

藥品合約製造市場有望顯著成長，這主要是由於對產品推向市場的效率和靈活性的需求所推動的。營運專業知識、先進設備和專業設施等因素正在推動營運外包的興起。值得注意的是，透過將製造業務外包給全球CMO和CDMO，企業可以實現供應鏈多元化，並降低與政治和經濟不確定性相關的風險。此外，自動化、連續製造和數據分析等先進技術的整合提高了生產能力並確保了高品質的結果。在快速發展的製藥行業中，合約製藥製造商擁有應對複雜監管環境、優化製造工作流程以及支持從臨床試驗到商業規模製造的無縫過渡的專業知識。上述因素可能會在預測期內為合約服務提供者帶來有利的市場成長機會。

本報告調查了全球藥品合約製造市場，並提供了市場概況，以及按製造產品類型、原料藥類型、原料藥藥理活性、FDF 類型、劑型和包裝類型進行的細分。最終用戶、地區和進入市場的公司概況提供趨勢。

目錄

第一章前言

第二章研究方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

第 6 章藥品合約生產：監管狀況

第七章藥品合約生產：市場狀況

第 8 章區域能力

第九章公司簡介

第 10 章簡介

第 11 章製造與採購的決策架構

第十二章併購

第 13 章近期擴展

第14章能力分析

第十五章需求分析

第 16 章市場影響分析：推動因素、阻礙因素、機會、挑戰

第十七章全球藥品合約製造市場

第十八章藥品合約製造市場（依製造產品類型）

第十九章醫藥 API 合約製造市場（依 API 類型）

第20章醫藥API合約生產市場（以API藥理活性）

第21章醫藥FDF合約製造市場（依FDF類型）

第22章醫藥FDF合約製造市場（以劑型）

第23章藥品合約製造市場（依包裝類型）

第 24 章藥品合約製造市場（按最終用戶）

第25章藥品合約製造市場（依業務規模）

第26章藥品合約生產市場（依主要地區）

第27章藥品合約製造市場（主要公司）

第28章案例研究：小分子藥物與高分子藥物/療法的比較

第29章結論

第 30 章高階主管見解

  • 章節概述
  • Ajinomoto Althea
  • Bachem
  • CiVentiChem
  • CordenPharma
  • Helsinn Group
  • Novasep
  • Sovereign Pharma
  • Wavelength Pharmaceuticals

第 31 章附錄一：表格資料

第32章附錄二：公司與組織名單

Product Code: RA100285

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global pharmaceutical contract manufacturing market is estimated to grow from USD 99 billion in the current year to USD 156 billion by 2035, at a CAGR of 4.3% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product Manufactured

  • API & Intermediates
  • FDF

Type of API

  • Originator API
  • Generic API

API Potency

  • Low Potent API
  • High Potent API

Type of FDF

  • Originator FDF
  • Generic FDF

Dosage Form

  • Oral Solids
  • Liquids
  • Emulsions
  • Other Dosage Forms

Type of Packaging Offered

  • Bottles
  • Blisters
  • Parenteral
  • Others

Scale of Operation

  • Clinical
  • Commercial

Type of End-user

  • Small Companies
  • Mid-sized Companies
  • Large and Very Large Companies

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

The pharmaceutical contract manufacturing market is poised for significant growth, primarily driven by the demand for efficiency and flexibility in bringing products to the market. Factors such as operational expertise, advanced equipment and specialized facilities have led to an increase in outsourcing operations. It is worth highlighting that by outsourcing manufacturing operations to CMOs and CDMOs with a global footprint, companies can diversify their supply chains and reduce risks associated with political and economic uncertainties. Moreover, the integration of advanced technologies, such as automation, continuous manufacturing and data analytics, boosts production capabilities and ensures high-quality outcomes. With the rapidly evolving pharmaceutical landscape, contract manufacturers bring expertise in navigating complex regulatory frameworks, optimizing production workflows, and supporting a seamless transition from clinical studies to commercial scale manufacturing. The aforementioned factors are likely to present lucrative market growth opportunities for contract service providers during the forecast period.

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the pharmaceutical contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, close to 425 organizations offer pharmaceutical contract manufacturing services; of these, majority of the CMOs provide fill-finish / packaging and labelling services.

2. A relatively larger proportion of CMOs manufacture FDFs; close to 15% of the players have the required capabilities to manufacture all types of finished dosage forms.

3. In pursuit of building a competitive edge and to establish themselves as one-stop shops, stakeholders are actively consolidating their capabilities related to small molecule manufacturing through mergers and acquisitions.

4. In order to meet the rising demand for APIs and finished products, CMOs have made elaborate investments in expanding their existing capacities and capabilities; this trend is most pronounced in the US and India.

5. The global pharmaceutical contract manufacturing capacity is well distributed across different facilities worldwide; notably, large and very large players account for 80% of the total capacity.

6. Owing to the increase in outsourcing activity for small molecule manufacturing operations, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly over the decade.

7. In the past decade, a shift in trend has been observed in the pharmaceutical contract manufacturing industry as more players have set up their manufacturing facilities in developing regions across Asia-Pacific.

8. Driven by the increasing pace of expansions and mergers between the stakeholders in this domain, the market for pharmaceutical contract manufacturing is poised to witness steady growth in the foreseeable future.

9. The pharmaceutical contract manufacturing market is anticipated to grow at a steady rate, till 2035; North America is expected to capture the majority share (over 35%) of the market by 2035.

10. In the long term, small and mid-sized companies are likely to drive the growth of the pharmaceutical contract manufacturing market; oral solids is expected to capture the majority share (~50%) by 2035.

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

FDF segment is Likely to Dominate the Pharmaceutical Contract Manufacturing Market During the Forecast Period

Based on the type of product manufactured, the market is segmented into API & Intermediates and FDF. It is worth highlighting that majority of the current pharmaceutical contract manufacturing market is captured by the FDF segment and this trend is likely to remain the same in the forthcoming years. This can be attributed to the growing demand for ready-to-make products, high value addition and stringent regulatory guidelines.

Currently, Generic and Originator APIs Hold Similar Market Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of APIs, the market is segmented into generic API and originator API. It is worth highlighting that, at present, both generic and originator APIs capture almost similar market share in the pharmaceutical contract manufacturing market. This can be attributed to competitive pricing and quality standards maintained by generic manufacturers. It is worth noting that there is continued demand for branded drugs from originator companies.

High Potent API Segment is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market

Based on the types of API by potency, the market is segmented into low potent API and high potent API. Owing to their enhanced efficacy, lower dosage requirements and increasing demand for targeted therapies, the highly potent API (HPAPI) market is likely to grow at a relatively higher CAGR.

Currently, Originator FDF Occupies the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of FDFs, the market is segmented into generic FDF and originator FDF. Owing to brand loyalty, ongoing investments in research and development, and established market presence, the originator FDF holds the maximum share within the pharmaceutical contract manufacturing market.

Liquid Dosage Form is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market

Based on the dosage forms, the market is segmented into oral solids, liquids, emulsions and others. It is worth highlighting that, due to the simplicity of administration, growing applications in pediatric and geriatric populations and enhanced patient adherence, liquids are likely to grow at a higher CAGR in the forthcoming years.

Currently, Bottles Occupy the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of packaging offered, the market is segmented into bottles, blisters, parenterals and others. It is worth highlighting that, at present, bottles hold the maximum share within the pharmaceutical contract manufacturing market. Bottles offer various advantages, such as cost-effectiveness, versatility and capability to accommodate various types of formulations and dosages.

By Scale of Operation, Commercial Scale is Likely to Dominate the Pharmaceutical Contract Manufacturing Market

Based on the scale of operation, the market is segmented into clinical and commercial scale. Whilst commercial scale manufacturing will be the primary driver of the overall market, it is worth highlighting that the pharmaceutical contract manufacturing market at the clinical scale is likely to grow at a relatively higher CAGR.

Small Companies Account for the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of end-user, the market is segmented into small, mid-sized, and large and very large companies. It is worth highlighting that, at present, small companies capture the highest share within the pharmaceutical manufacturing market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Majority share is expected to be captured by contract manufacturers based in North America. It is worth highlighting that over the years, the market for Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Pharmaceutical Contract Manufacturing Market

  • AMRI Global
  • Altasciences
  • Cambrex
  • Catalent
  • DPT Laboratories
  • Aenova
  • Almac
  • Corden Pharma
  • Fresenius Kabi
  • Glatt
  • Hovione
  • Recipharm
  • Siegfried
  • CMIC Group
  • Nectar Lifesciences
  • Syngene
  • WuXi AppTec

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Former Director of Business Development, Ajinomoto Althea
  • Former Chief Executive Officer, Bachem
  • President and Chief Executive Officer, CiVentiChem
  • Digitalization and Artificial Intelligence Manager, CordenPharma
  • Former Director, Commercial Development, Helsinn Group
  • Former Director, Pharmaceuticals Marketing, Novasep
  • Director, Operations, Sovereign Pharma
  • Former Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the pharmaceutical contract manufacturing market, focusing on key market segments, including [A] type of product manufactured, [B] type of API, [C] API potency, [D] type of FDF, [E] dosage form, [F] type of packaging offered, [G] scale of operation, [H] end users and [I] key geographical regions.
  • Regulatory Landscape: A discussion on general regulatory guidelines across different countries, featuring an elaborative assessment of various CMOs in the pharmaceutical contract manufacturing industry, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • Market Landscape: A comprehensive evaluation of companies involved in contract manufacturing of small molecules, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of manufacturer, [F] type of services offered, [G] type of finished dosage form manufactured, [H] type of packaging offered and [I] scale of operation.
  • Regional Capability Analysis: A detailed analysis of the capabilities of pharmaceutical contract manufacturing facilities in different regions (North America, Europe, Asia-Pacific and the Rest of the World) across the globe.
  • Company Profiles: In-depth profiles of key industry players in pharmaceutical contract manufacturing market, focusing on [A] company overviews, [B] manufacturing portfolio, [C] financial information, [D] recent developments and [E] an informed future outlook.
  • Additional Insights: An insightful framework that emphasizes the key indicators and factors that need to be considered by pharmaceutical drug developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
  • Merger and Acquisitions: A comprehensive examination of the various mergers and acquisitions, focusing on multiple relevant parameters, including [A] year of agreement, [B] type of agreement, [C] key value drivers of the deal, [D] most active players (in terms of number of agreements signed) and [E] geographical location of the companies. In addition, the chapter provides information on the financial terms of the deals (if available) in order to enumerate the deal multiples (in terms of annual revenues of the acquired firm (at the time of acquisition) and years of experience in this domain).
  • Acquisitions: An analysis of acquisitions has taken place in the pharmaceutical contract manufacturing domain, since 2017.
  • Capacity Analysis: Estimation of global pharmaceutical manufacturing capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size and [B] key geographical regions.
  • Demand Analysis: Informed estimates of the annual commercial and clinical demand for small molecule drugs across key geographical regions.
  • Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What is the current global demand for small molecules?
  • What percentage of the pharmaceutical manufacturing operations are presently outsourced?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Considerations
    • 2.6.1. Demographics
    • 2.6.2. Economic Factors
    • 2.6.3. Government Regulations
    • 2.6.4. Supply Chain
    • 2.6.5. COVID Impact / Related Factors
    • 2.6.6. Market Access
    • 2.6.7. Healthcare Policies
    • 2.6.8. Industry Consolidation
  • 2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Types of Third-party Manufacturers
  • 5.3. Overview of Pharmaceutical Contract Manufacturing
  • 5.4. Evolution of Pharmaceutical Contract Manufacturing
    • 5.4.1. Traditional Pharmaceutical CMOs
    • 5.4.2. Modern Pharmaceutical CMOs
  • 5.5. Need for Outsourcing in the Pharmaceutical Industry
  • 5.6. Services Offered by CMOs
  • 5.7. Key Considerations While Selecting a CMO
  • 5.8. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
  • 5.9. Recent Developments in the Pharmaceutical Contract Manufacturing Industry
    • 5.9.1. Integration of Artificial Intelligence
    • 5.9.2. Strategic Partnerships and Collaborations
      • 5.9.2.1. Strategic Long-Term Alliance
      • 5.9.2.2. Flexible Short-Term Partnership Agreements
    • 5.9.3. Integrated End-to-End Business Model
    • 5.9.4. Dependence on Software Service Providers
  • 5.10. Future Perspectives

6. PHARMACEUTICAL CMOs: REGULATORY LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Regulatory Guidelines in North America
    • 6.2.1. Landscape in the US
    • 6.2.2. Landscape in Canadian
  • 6.3. Regulatory Guidelines in Europe
  • 6.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
    • 6.4.1. Landscape in China
    • 6.4.2. Landscape in India
    • 6.4.3. Landscape in Japan
    • 6.4.4. Landscape in South Korea
    • 6.4.5 Landscape in Australia
    • 6.4.6. Landscape in Brazil
  • 6.5. Analysis of Pharmaceutical CMOs by Approval Received from Regulatory Authorities
  • 6.6. Regulatory Landscape: Regional Benchmarking Analysis

7. PHARMACEUTICAL CMOs: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Pharmaceutical CMOs: List of Companies
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Location of Manufacturing Facility
    • 7.2.5. Analysis by Product Manufacturing Capability
    • 7.2.6. Analysis by Type of Product Manufactured
    • 7.2.7. Analysis by Type of Service Offered
    • 7.2.8. Analysis by Type of Finished Dosage Form Manufactured
    • 7.2.9. Analysis by Type of Packaging Offered
    • 7.2.10. Analysis by Scale of Operation

8. REGIONAL CAPABILITY

  • 8.1. Chapter Overview
  • 8.2. Key Assumptions and Methodology
  • 8.3. Overall Landscape of Pharmaceutical Contract Manufacturing Facilities
    • 8.3.1. Pharmaceutical Contract Manufacturing Facilities in North America
    • 8.3.2. Pharmaceutical Contract Manufacturing Facilities in Europe
    • 8.3.3. Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific
    • 8.3.4. Pharmaceutical Contract Manufacturing Facilities in Rest of the World

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Pharmaceutical CMOs based in North America
    • 9.2.1. AMRI Global
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Service Portfolio
      • 9.2.1.3. Recent Developments and Future Outlook
    • 9.2.2. Altasciences
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Service Portfolio
      • 9.2.2.3. Recent Developments and Future Outlook
    • 9.2.3. Cambrex
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Service Portfolio
      • 9.2.3.3. Recent Developments and Future Outlook
    • 9.2.4. Catalent
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Information
      • 9.2.4.3. Service Portfolio
      • 9.2.4.4. Recent Developments and Future Outlook
    • 9.2.5. DPT Laboratories
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Service Portfolio
      • 9.2.5.3. Recent Developments and Future Outlook
  • 9.3. Pharmaceutical CMOs based in Europe
    • 9.3.1. Aenova
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Information
      • 9.3.1.3. Service Portfolio
      • 9.3.1.4. Recent Developments and Future Outlook
    • 9.3.2. Almac
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Information
      • 9.3.2.3. Service Portfolio
      • 9.3.2.4. Recent Developments and Future Outlook
    • 9.3.3. CordenPharma
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Service Portfolio
      • 9.3.3.3. Recent Developments and Future Outlook
    • 9.3.4. Fresenius Kabi
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Information
      • 9.3.4.3. Service Portfolio
      • 9.3.4.4. Recent Developments and Future Outlook
    • 9.3.5. Glatt
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Service Portfolio
      • 9.3.5.3. Recent Developments and Future Outlook
    • 9.3.6. Hovione
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Service Portfolio
      • 9.3.6.3. Recent Developments and Future Outlook
    • 9.3.7. Recipharm
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Information
      • 9.3.7.3. Service Portfolio
      • 9.3.7.4. Recent Developments and Future Outlook
    • 9.3.8. Siegfried
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Information
      • 9.3.8.3. Service Portfolio
      • 9.3.8.4. Recent Developments and Future Outlook
  • 9.4. Pharmaceutical CMOs based in Asia-Pacific and Rest of the World
    • 9.4.1. CMIC Group
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Information
      • 9.4.1.3. Service Portfolio
      • 9.4.1.4. Recent Developments and Future Outlook
    • 9.4.2. Nectar Lifesciences
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Information
      • 9.4.2.3. Service Portfolio
      • 9.4.2.4. Recent Developments and Future Outlook
    • 9.4.3. Syngene
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Information
      • 9.4.3.3. Service Portfolio
      • 9.4.3.4. Recent Developments and Future Outlook
    • 9.4.4. WuXi AppTec
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Information
      • 9.4.4.3. Service Portfolio
      • 9.4.1.4. Recent Developments and Future Outlook

10. SHORT PROFILES

  • 10.1. Chapter Overview
  • 10.2. Players based in North America
    • 10.2.1. Albemarle
    • 10.2.2. Baxter
    • 10.2.3. Patheon
    • 10.2.4. West Pharmaceutical Services
  • 10.3. Players based in Europe
    • 10.3.1. Eurofins Scientific
    • 10.3.2. Evonik
    • 10.3.3. Fareva
    • 10.3.4. GlaxoSmithKline
    • 10.3.5. Lonza
  • 10.4. Players based in Asia-Pacific and Rest of the World
    • 10.4.1. Alkem Laboratories
    • 10.4.2. Aspen Pharmacare
    • 10.4.3. MSN Laboratories
    • 10.4.4. Teva Pharmaceuticals
    • 10.4.5. UBE Corporation

11. MAKE VERSUS BUY DECISION FRAMEWORK

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Key Parameters
  • 11.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
    • 11.3.1. Scenario 1
    • 11.3.2. Scenario 2
    • 11.3.3. Scenario 3
    • 11.3.4. Scenario 4
  • 11.4. Concluding Remarks

12. MERGERS AND ACQUISITIONS

  • 12.1. Chapter Overview
  • 12.2. Merger and Acquisition Models
  • 12.3. Pharmaceutical Contract Manufacturing: Mergers and Acquisitions
    • 12.3.1. Analysis by Year of Agreement
    • 12.3.2. Analysis by Type of Agreement
    • 12.3.3. Analysis by Type of Acquisition
    • 12.3.4. Analysis by Focus Area
    • 12.3.5. Analysis by Type of Business Segment
    • 12.3.6. Analysis by Type of Service Offered
    • 12.3.7. Analysis by Scale of Operation
    • 12.3.8. Analysis by Geography
    • 12.3.9. Analysis by Location of Manufacturing Facility
    • 12.3.10. Analysis by Key Value Drivers
    • 12.3.11. Analysis by Year of Acquisition and Key Value Drivers
    • 12.3.12. Most Active Acquirers: Analysis by Number of Acquisitions
  • 12.4. Key Acquisitions: Analysis by Deal Multiples

13. RECENT EXPANSIONS

  • 13.1. Chapter Overview
  • 13.2. Type of Expansions
  • 13.2. Pharmaceutical CMOs: Recent Expansions
    • 13.2.1. Analysis by Year of Expansion
    • 13.2.2. Analysis by Type of Expansion
    • 13.2.3. Analysis by Purpose of Expansion
    • 13.2.4. Analysis by Year and Purpose of Expansion
    • 13.2.5. Analysis by Type of Business Segment
    • 13.2.6. Analysis by Type of API Manufactured
    • 13.2.7. Analysis by Type of Service Offered
    • 13.2.8. Analysis by Scale of Operation
    • 13.2.9. Analysis by Capital Invested
    • 13.2.10. Analysis by Location of Headquarters
    • 13.2.11. Analysis by Location of Manufacturing Facility
    • 13.2.12. Most Active Players: Analysis by Number of Recent Expansions

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Scale of Operation
    • 14.3.2. Analysis by Location of Headquarters
    • 14.3.3. Analysis by Location of Manufacturing Facilities
      • 14.3.3.1. Pharmaceutical Contract Manufacturing Capacity in North America
      • 14.3.3.2. Pharmaceutical Contract Manufacturing Capacity in Europe
      • 14.3.3.3. Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  • 14.4. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
    • 15.2.1. Overall Annual Demand for Small Molecule APIs, till 2035
    • 15.2.2. Annual Commercial Demand for Small Molecule APIs: Distribution by Geography, Current Year and 2035
      • 15.2.2.1. Annual Commercial Demand for Small Molecule APIs in North America, till 2035
      • 15.2.2.2. Annual Commercial Demand for Small Molecule APIs in Europe, till 2035
      • 15.2.2.3. Annual Commercial Demand for Small Molecule APIs in Asia-Pacific, till 2035
      • 15.2.2.4. Annual Commercial Demand for Small Molecule APIs in Rest of the World, till 2035
    • 15.2.3. Annual Clinical Demand for Small Molecule APIs: Distribution by Trial Phase, Current Year and 2035
      • 15.2.3.1. Annual Clinical Demand for Small Molecule APIs in Phase I Trials, till 2035
      • 15.2.3.2. Annual Clinical Demand for Small Molecule APIs in Phase II Trials, till 2035
      • 15.2.3.3. Annual Clinical Demand for Small Molecule APIs in Phase III Trials, till 2035
  • 15.3. Annual Demand vs Capacity

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Pharmaceutical Contract Manufacturing Market, Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segments

18. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT MANUFACTURED

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured, Current Year and 2035
    • 18.3.1. Pharmaceutical Contract Manufacturing Market for API and Intermediates: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 18.3.2. Pharmaceutical Contract Manufacturing Market for FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 18.4. Data Triangulation and Validation

19. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY TYPE OF API

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Pharmaceutical API Contract Manufacturing Market: Distribution by Type of API, Current Year and 2035
    • 19.3.1. Pharmaceutical API Contract Manufacturing Market for Generic API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 19.3.2. Pharmaceutical API Contract Manufacturing Market for Originator API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 19.4. Data Triangulation and Validation

20. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY API POTENCY

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Pharmaceutical API Contract Manufacturing Market: Distribution by API Potency, Current Year and 2035
    • 20.3.1. Pharmaceutical API Contract Manufacturing Market for Low Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 20.3.2. Pharmaceutical API Contract Manufacturing Market for High Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 20.4. Data Triangulation and Validation

21. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY TYPE OF FDF

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Type of FDF, Current Year and 2035
    • 21.3.1. Pharmaceutical FDF Contract Manufacturing Market for Generic FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 21.3.2. Pharmaceutical FDF Contract Manufacturing Market for Originator FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 21.4. Data Triangulation and Validation

22. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY DOSAGE FORM

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Dosage Form, Current Year and 2035
    • 22.3.1. Pharmaceutical FDF Contract Manufacturing Market for Oral Solids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 22.3.2. Pharmaceutical FDF Contract Manufacturing Market for Liquids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 22.3.3. Pharmaceutical FDF Contract Manufacturing Market for Emulsions: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 22.3.4. Pharmaceutical FDF Contract Manufacturing Market for Other Dosage Forms: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 22.4. Data Triangulation and Validation

23. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PACKAGING OFFERED

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered, Current Year and 2035
    • 23.3.1. Pharmaceutical Contract Manufacturing Market for Bottles: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 23.3.2. Pharmaceutical Contract Manufacturing Market for Blisters: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 23.3.3. Pharmaceutical Contract Manufacturing Market for Parenteral: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 23.3.4. Pharmaceutical Contract Manufacturing Market for Others: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 23.4. Data Triangulation and Validation

24. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END-USERS

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Pharmaceutical Contract Manufacturing Market: Distribution by End-users, Current Year and 2035
    • 24.3.1. Pharmaceutical Contract Manufacturing Market for Small Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 24.3.2. Pharmaceutical Contract Manufacturing Market for Mid-sized Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 24.3.3. Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 24.4. Data Triangulation and Validation

25. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, Current Year and 2035
    • 25.3.1. Pharmaceutical Contract Manufacturing Market for Clinical: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 25.3.2. Pharmaceutical Contract Manufacturing Market for Commercial: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 25.4. Data Triangulation and Validation

26. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 26.1. Chapter Overview
  • 26.2. Key Assumptions and Methodology
  • 26.3. Pharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, Current Year and 2035
    • 26.3.1. Pharmaceutical Contract Manufacturing Market in North America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 26.3.2. Pharmaceutical Contract Manufacturing Market in Europe: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 26.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 26.3.2. Pharmaceutical Contract Manufacturing Market in Latin America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
    • 26.3.3. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 26.4. Data Triangulation and Validation

27. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

  • 27.1. Chapter Overview
  • 27.2. Key Assumptions and Methodology
  • 27.3. Pharmaceutical Contract Manufacturing Market, by Leading Players
  • 27.4. Data Triangulation and Validation

28. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES

  • 28.1. Chapter Overview
  • 28.2. Small Molecule and Large Molecule Drugs / Therapies
    • 28.2.1. Comparison of General Characteristics
    • 28.2.2. Comparison of Key Specifications
    • 28.2.3. Comparison of Manufacturing Processes
    • 28.2.4. Comparison of Key Manufacturing-related Challenges

29. CONCLUDING REMARKS

30. EXECUTIVE INSIGHTS

  • 30.1. Chapter Overview
  • 30.2. Ajinomoto Althea
    • 30.2.1. Company Snapshot
    • 30.2.2. Interview Transcript: Scott Goldstein, Former Director of Business Development
  • 30.3. Bachem
    • 30.3.1. Company Snapshot
    • 30.3.2. Interview Transcript: Thomas Fruh, Former Chief Executive Officer
  • 30.4. CiVentiChem
    • 30.4.1. Company Snapshot
    • 30.4.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
  • 30.5. CordenPharma
    • 30.5.1. Company Snapshot
    • 30.5.2. Interview Transcript: Roberto Margartia, Digitalization and Artificial Intelligence Manager
  • 30.6. Helsinn Group
    • 30.6.1. Company Snapshot
    • 30.6.2. Interview Transcript: Allison Vavala, Former Director, Commercial Development
  • 30.7. Novasep
    • 30.7.1. Company Snapshot
    • 30.7.2. Interview Transcript: Kevin Daley, Former Director, Pharmaceuticals Marketing
  • 30.8. Sovereign Pharma
    • 30.8.1. Company Snapshot
    • 30.8.2. Interview Transcript: Piyush Desai, Director, Operations
  • 30.9. Wavelength Pharmaceuticals
    • 30.9.1. Company Snapshot
    • 30.9.2. Interview Transcript: Ilan Avni, Former Vice President Business Development, Marketing, and IP

31. APPENDIX I: TABULATED DATA

32. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 6.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
  • Table 6.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
  • Table 6.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
  • Table 7.1 Pharmaceutical CMOs: List of Companies
  • Table 7.2 Pharmaceutical CMOs: Information on Product Manufacturing Capability and Type of Product Manufactured
  • Table 7.3 Pharmaceutical CMOs: Information on Type of Service Offered
  • Table 7.4 Pharmaceutical CMOs: Information on Type of Finished Dosage Form Manufactured
  • Table 7.5 Pharmaceutical CMOs: Information on Type of Packaging Offered
  • Table 7.6 Pharmaceutical CMOs: Information on Scale of Operation
  • Table 8.1 Pharmaceutical CMOs: Information on Manufacturing Facilities in North America
  • Table 8.2 Pharmaceutical CMOs: Information on Manufacturing Facilities in Europe
  • Table 8.3 Pharmaceutical CMOs: Information on Manufacturing Facilities in Asia-Pacific
  • Table 8.4 Pharmaceutical CMOs: Information on Manufacturing Facilities in Rest of the World
  • Table 9.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
  • Table 9.2 AMRI: Company Overview
  • Table 9.3 AMRI: Service Portfolio
  • Table 9.4 AMRI: Recent Developments and Future Outlook
  • Table 9.5 Altasciences: Company Overview
  • Table 9.6 Altasciences: Service Portfolio
  • Table 9.7 Altasciences: Recent Developments and Future Outlook
  • Table 9.8 Cambrex: Company Overview
  • Table 9.9 Cambrex: Service Portfolio
  • Table 9.10 Cambrex: Recent Developments and Future Outlook
  • Table 9.11 Catalent: Company Overview
  • Table 9.12 Catalent: Service Portfolio
  • Table 9.13 Catalent: Recent Developments and Future Outlook
  • Table 9.14 DPT Laboratories: Company Overview
  • Table 9.15 DPT Laboratories: Service Portfolio
  • Table 9.16 DPT Laboratories: Recent Developments and Future Outlook
  • Table 9.17 Aenova: Company Overview
  • Table 9.18 Aenova: Service Portfolio
  • Table 9.19 Aenova: Recent Developments and Future Outlook
  • Table 9.20 Almac: Company Overview
  • Table 9.21 Almac: Service Portfolio
  • Table 9.22 Almac: Recent Developments and Future Outlook
  • Table 9.23 CordenPharma: Company Overview
  • Table 9.24 CordenPharma: Service Portfolio
  • Table 9.25 CordenPharma: Recent Developments and Future Outlook
  • Table 9.26 Fresenius Kabi: Company Overview
  • Table 9.27 Fresenius Kabi: Service Portfolio
  • Table 9.28 Fresenius Kabi: Recent Developments and Future Outlook
  • Table 9.29 Glatt: Company Overview
  • Table 9.30 Glatt: Service Portfolio
  • Table 9.31 Glatt: Recent Developments and Future Outlook
  • Table 9.32 Hovione: Company Overview
  • Table 9.33 Hovione: Service Portfolio
  • Table 9.34 Hovione: Recent Developments and Future Outlook
  • Table 9.35 Recipharm: Company Overview
  • Table 9.36 Recipharm: Service Portfolio
  • Table 9.37 Recipharm: Recent Developments and Future Outlook
  • Table 9.38 Siegfried: Company Overview
  • Table 9.39 Siegfried: Service Portfolio
  • Table 9.40 Siegfried: Recent Developments and Future Outlook
  • Table 9.41 CMIC Group: Company Overview
  • Table 9.42 CMIC Group: Service Portfolio
  • Table 9.43 CMIC Group: Recent Developments and Future Outlook
  • Table 9.44 Nectar Lifesciences: Company Overview
  • Table 9.45 Nectar Lifesciences: Service Portfolio
  • Table 9.46 Nectar Lifesciences: Recent Developments and Future Outlook
  • Table 9.47 Syngene: Company Overview
  • Table 9.48 Syngene: Service Portfolio
  • Table 9.49 Syngene: Recent Developments and Future Outlook
  • Table 9.50 WuXi AppTec: Company Overview
  • Table 9.51 WuXi AppTec: Service Portfolio
  • Table 9.52 WuXi AppTec: Recent Developments and Future Outlook
  • Table 10.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
  • Table 10.2 Albemarle: Company Overview
  • Table 10.3 Baxter: Company Overview
  • Table 10.4 Patheon: Company Overview
  • Table 10.5 West Pharmaceutical Services: Company Overview
  • Table 10.6 Eurofins Scientific: Company Overview
  • Table 10.7 Evonik: Company Overview
  • Table 10.8 Fareva: Company Overview
  • Table 10.9 GlaxoSmithKline: Company Overview
  • Table 10.10 Lonza: Company Overview
  • Table 10.11 Alkem Laboratories: Company Overview
  • Table 10.12 Aspen Pharmacare: Company Overview
  • Table 10.13 MSN Laboratories: Company Overview
  • Table 10.14 Teva Pharmaceuticals: Company Overview
  • Table 10.15 UBE Corporation: Company Overview
  • Table 12.1 Pharmaceutical Contract Manufacturing: List of Mergers and Acquisitions
  • Table 12.2 Mergers and Acquisitions: Deal Multiples, since 2017
  • Table 13.1 Pharmaceutical Contract Manufacturing: List of Expansions
  • Table 14.1 Global Production Capacity for Pharmaceutical Contract Manufacturing: Average Capacity by Size of CMOs (Sample Data Set)
  • Table 14.2 Global Production Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
  • Table 15.1 Demand Analysis: Annual Outsourced Demand for Small Molecules, till 2035 (Metric Tons)
  • Table 15.2 Pharmaceutical Contract Manufacturing: Annual Supply for Outsourcing, till 2035 (Million Liters)
  • Table 27.1 List of Leading Pharmaceutical Contract Manufacturing Companies
  • Table 28.1 Small Molecules and Large Molecules: Strengths and Weaknesses
  • Table 28.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
  • Table 28.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
  • Table 30.1 Ajinomoto Althea: Key Highlights
  • Table 30.2 Bachem: Key Highlights
  • Table 30.3 CiVentiChem: Key Highlights
  • Table 30.4 Helsinn: Key Highlights
  • Table 30.5 Novasep: Key Highlights
  • Table 30.6 Sovereign Pharma: Key Highlights
  • Table 30.7 Wavelength Pharmaceuticals: Key Highlights
  • Table 32.1 Pharmaceutical CMOs: Distribution by Year of Establishment
  • Table 32.2 Pharmaceutical CMOs: Distribution by Company Size
  • Table 32.3 Pharmaceutical CMOs: Distribution by Location of Headquarters (Region)
  • Table 32.4 Pharmaceutical CMOs: Distribution by Location of Headquarters (Country)
  • Table 32.5 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
  • Table 32.6 Pharmaceutical CMOs: Distribution by Product Manufacturing Capability
  • Table 32.7 Pharmaceutical CMOs: Distribution by Type of Product Manufactured
  • Table 32.8 Pharmaceutical CMOs: Distribution by Type of Service Offered
  • Table 32.9 Pharmaceutical CMOs: Distribution by Type of Finished Dosage Form Manufactured
  • Table 32.10 Pharmaceutical CMOs: Distribution by Type of Packaging Offered
  • Table 32.11 Pharmaceutical CMOs: Distribution by Scale of Operation
  • Table 32.12 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
  • Table 32.13 Pharmaceutical CMOs: Distribution of Pharmaceutical Contract Manufacturers by Scale of Operation
  • Table 32.14 Catalent: Annual Revenue, FY 2019 Onwards (USD Billion)
  • Table 32.15 Aenova: Annual Revenue, FY 2019 Onwards (EUR Million)
  • Table 32.16 Almac: Annual Revenue, FY 2019 Onwards (Pound Million)
  • Table 32.17 Fresenius Kabi: Annual Revenues, FY 2019 Onwards (EUR Million)
  • Table 32.18 Recipharm: Annual Revenues, FY 2019 Onwards (SEK Million)
  • Table 32.19 Siegfried: Annual Revenues, FY 2019 Onwards (CHF Billion)
  • Table 32.20 CMIC Group: Annual Revenues, FY 2019 Onwards (JPY Billion)
  • Table 32.21 Nectar Lifesciences: Annual Revenues, FY 2019 Onwards (INR Billion)
  • Table 32.22 Syngene: Annual Revenues, FY 2019 Onwards (INR Billion)
  • Table 32.23 WuXi AppTec: Revenues, FY 2019 Onwards (RMB Billion)
  • Table 32.24 Mergers and Acquisitions: Distribution by Year of Agreement, since 2017
  • Table 32.25 Mergers and Acquisitions: Distribution by Type of Agreement
  • Table 32.26 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Table 32.27 Mergers and Acquisitions: Distribution by Focus Area
  • Table 32.28 Mergers and Acquisitions: Distribution by Type of Business Segment
  • Table 32.29 Mergers and Acquisitions: Distribution by Type of Service Offered
  • Table 32.30 Mergers and Acquisitions: Distribution by Scale of Operation
  • Table 32.31 Mergers and Acquisitions: Distribution by Type of Acquisition and Scale of Operation
  • Table 32.32 Mergers and Acquisitions: Distribution by Geography
  • Table 32.33 Mergers and Acquisitions: Distribution by Location of Manufacturing Facility
  • Table 32.34 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 32.35 Mergers and Acquisitions: Distribution by Year of Acquisitions and Key Value Drivers
  • Table 32.36 Most Active Acquirers: Distribution by Number of Acquisitions
  • Table 32.37 Key Acquirers: Distribution by Deal Multiples based on Revenue
  • Table 32.38 Recent Expansions: Distribution by Year of Expansion, since 2017
  • Table 32.39 Recent Expansions: Distribution by Type of Expansion
  • Table 32.40 Recent Expansions: Distribution by Purpose of Expansion
  • Table 32.41 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Table 32.42 Recent Expansions: Distribution by Type of Business Segment
  • Table 32.43 Recent Expansions: Distribution by Type of API Manufactured
  • Table 32.44 Recent Expansions: Distribution by Type of Service Offered
  • Table 32.45 Recent Expansions: Distribution by Scale of Operation
  • Table 32.46 Recent Expansions: Distribution by Capital Invested (USD Million)
  • Table 32.47 Recent Expansions: Distribution by Purpose of Expansion and Capital Invested (USD Million)
  • Table 32.48 Recent Expansions: Distribution by Location of Headquarters
  • Table 32.49 Recent Expansions: Distribution by Capital Invested (USD Million) and Location of Headquarters
  • Table 32.50 Recent Expansions: Distribution by Location of Manufacturing Facility
  • Table 32.51 Most Active Players: Distribution by Number of Recent Expansions
  • Table 32.52 Global Production Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs (Sample Data Set)
  • Table 32.53 Global Production Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
  • Table 32.54 Global Production Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Headquarters
  • Table 32.55 Global Production Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Region-wise)
  • Table 32.56 Demand Analysis: Annual Demand for Small Molecule APIs, till 2035 (Metric Ton)
  • Table 32.57 Demand Analysis: Demand Analysis: Commercial Demand for Small Molecule APIs: Distribution by Geography, Current Year and 2035 (Metric Ton)
  • Table 32.58 Demand Analysis: Commercial Demand for Small Molecule APIs in North America, till 2035 (Metric Ton)
  • Table 32.59 Demand Analysis: Commercial Demand for Small Molecule APIs in Europe, till 2035 (Metric Ton)
  • Table 32.60 Demand Analysis: Commercial Demand for Small Molecule APIs in Asia-Pacific, till 2035 (Metric Ton)
  • Table 32.61 Demand Analysis: Commercial Demand for Small Molecule APIs in Rest of the World, till 2035 (Metric Ton)
  • Table 32.62 Demand Analysis: Clinical Demand for Small Molecule APIs: Distribution by Trial Phase, till 2035 (Metric Ton)
  • Table 32.63 Demand Analysis: Clinical Demand for Small Molecule APIs in Phase I Trials, till 2035 (Metric Ton)
  • Table 32.64 Demand Analysis: Clinical Demand for Small Molecule APIs in Phase II Trials, till 2035 (Metric Ton)
  • Table 32.65 Demand Analysis: Clinical Demand for Small Molecule APIs in Phase III Trials, till 2035 (Metric Ton)
  • Table 32.66 Pharmaceutical Contract Manufacturing: Demand vs Capacity, till 2035
  • Table 32.67 Global Pharmaceutical Contract Manufacturing Market, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.68 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
  • Table 32.69 Global Pharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
  • Table 32.70 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured, Current Year and 2035
  • Table 32.71 Pharmaceutical Contract Manufacturing Market for API & Intermediates: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.72 Pharmaceutical Contract Manufacturing Market for FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.73 Pharmaceutical API Manufacturing Market: Distribution by Type of API, Current Year and 2035
  • Table 32.74 Pharmaceutical API Contract Manufacturing Market for Generic API: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.75 Pharmaceutical API Contract Manufacturing Market for Originator API: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.76 Pharmaceutical API Contract Manufacturing Market: Distribution by API Potency, Current Year and 2035
  • Table 32.77 Pharmaceutical API Contract Manufacturing Market for Low Potent API: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.78 Pharmaceutical API Contract Manufacturing Market for High Potent API: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.79 Pharmaceutical FDF Contract Manufacturing Market: Distribution by Type of FDF, Current Year and 2035
  • Table 32.80 Pharmaceutical FDF Contract Manufacturing Market for Generic FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.81 Pharmaceutical FDF Contract Manufacturing Market for Originator FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.82 Pharmaceutical Contract Manufacturing Market: Distribution by Dosage Form, Current Year and 2035
  • Table 32.83 Pharmaceutical FDF Contract Manufacturing Market for Oral Solids: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.84 Pharmaceutical FDF Contract Manufacturing Market for Liquids: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.85 Pharmaceutical FDF Contract Manufacturing Market for Emulsions: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.86 Pharmaceutical FDF Contract Manufacturing Market for Other Dosage Forms: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.87 Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered, Current Year and 2035
  • Table 32.88 Pharmaceutical Contract Manufacturing Market for Bottles: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.89 Pharmaceutical Contract Manufacturing Market for Blisters: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.90 Pharmaceutical Contract Manufacturing Market for Parenteral: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.91 Pharmaceutical Contract Manufacturing Market for Parenteral: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.92 Pharmaceutical Contract Manufacturing Market for Others: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.93 Pharmaceutical Contract Manufacturing Market: Distribution by End-user, Current Year and 2035
  • Table 32.94 Pharmaceutical Contract Manufacturing Market for Small Companies: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.95 Pharmaceutical Contract Manufacturing Market for Mid-sized Companies: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.96 Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.97 Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, Current Year and 2035
  • Table 32.98 Pharmaceutical Contract Manufacturing Market for Clinical: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.99 Pharmaceutical Contract Manufacturing Market for Commercial: Historical Trend (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.100 Pharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, Current Year and 2035
  • Table 32.101 Pharmaceutical Contract Manufacturing Market in North America: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.102 Pharmaceutical Contract Manufacturing Market in Europe: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.103 Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.104 Pharmaceutical Contract Manufacturing Market in Latin America: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)
  • Table 32.105 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa: Historical Trends (since 2017) and Forecasted Estimates (till 2035) (USD Billion)